Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports the successful use of abrocitinib for treating severe alopecia areata in a 14-year-old patient, demonstrating significant hair regrowth and suggesting the need for sustained JAK1 inhibition to prevent relapse.

In this review, researchers explore evidence showing that JAK inhibitors, particularly baricitinib and deuruxolitinib, are effective in promoting hair regrowth in severe alopecia areata while maintaining acceptable safety profiles, though long-term data remains scarce.

This review highlights that while low-dose oral minoxidil appears well-tolerated in cancer patients post-chemotherapy, its use during active chemotherapy has shown potential benefits but remains under investigation, with preclinical studies suggesting a protective effect against chemotherapy-induced alopecia.

In this study on C3H/HeJ-engrafted mice, a single injection of BMD-1141 significantly increased anagen hair follicle counts and enhanced hair regrowth compared to daily high-dose ruxolitinib, suggesting it stimulates hair growth by influencing the hair cycle rather than altering immune response.

This review discusses various therapeutic properties of bee venom, including its potential against cancer, infections, and inflammatory diseases, but notes limitations in clinical application due to variability and safety concerns, calling for further research.

This systematic review and meta-analysis suggest that oral minoxidil may be a safer and more effective option for children with hair disorders and refractory hypertension, though further large-scale trials are needed.

Minoxidil may improve nail growth and appearance.

Hydrogel microneedles with special nanoparticles and growth factor improve hair growth better than minoxidil for hair loss treatment.

Healthcare professionals need better training and systems for drug interaction reporting, injectable vitamin B12 helps tingling, oral helps numbness, probiotics may help ulcerative colitis, and more research is needed on Post-Finasteride Syndrome.

This systematic review and meta-analysis found that oral minoxidil improved hair loss symptoms in many patients, with significant improvement in 35%, but 27% experienced adverse events, highlighting the need for further research to confirm its safety and efficacy.

This study found that peimine treatment significantly improved wound healing and tissue regeneration in mice by enhancing wound closure, granulation tissue formation, and epidermal thickness, with effects linked to activation of the Notch1 signaling pathway.

This prospective study reported that 5 mg daily oral low-dose minoxidil over 24 weeks led to a high prevalence of hypertrichosis in 93% of male androgenetic alopecia patients, particularly affecting younger individuals, but generally had minimal impact on patients’ quality of life.

This study found that 808 nm laser photobiomodulation altered mitochondrial respiration and enhanced osteogenic protein expression in human dental pulp stem cells, with the effects being dose-specific and more pronounced at 15 J/cm².

In this study, researchers developed a carboxylated β-cyclodextrin formulation to enhance finasteride's physicochemical properties, achieving an encapsulation efficiency of about 85% and indicating potential for controlled drug release in therapeutic applications. Their findings suggest this inclusion complex could improve delivery of hydrophobic drugs like finasteride.

This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.

This study suggests that permanent chemotherapy-induced alopecia can occur in pediatric patients with Ewing's sarcoma and that treatments like minoxidil could be beneficial, though may not lead to full hair regrowth.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

This review reports that collagen peptides consistently provide modest improvements in skin hydration and elasticity and varying benefits for body composition and cardiometabolic markers, although effects on blood sugar control are less consistent; variations in source, dose, and study definitions limit generalizability.

This review reports that collagen peptides provide consistent, modest benefits for skin hydration and elasticity, with variable effects on body composition and cardiometabolic risk markers, though some outcomes remain inconsistent due to trial heterogeneity.

This consensus statement provides expert guidance on prescribing low-dose oral minoxidil for hair loss, noting a lack of representation of pediatric specialists and highlighting areas for future research.

This study found that MF patients with darker skin types show slower initial improvement with NB-UVB phototherapy, highlighting disparities in treatment efficacy that warrant further investigation.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

In this study, the integration of artificial intelligence in medicine was discussed, highlighting its potential to enhance diagnostic processes, optimize therapies, and provide advanced patient monitoring despite challenges like data inconsistency and limited model transparency.

This study found that more than half of patients with severe alopecia areata who reduced their baricitinib dose from 4mg to 2mg maintained a clinical response for up to 2 years.

In this study, a case of rosacea fulminans during pregnancy was successfully treated with a combination of oral azithromycin and prednisone, highlighting this treatment approach for managing similar cases.

This study found that among patients with inflammatory bowel disease, those with the NUDT15 mutation had a reduced tolerance for thiopurine dosage over the long term and were more likely to require hospitalization and surgery compared to those without the mutation.

In a systematic review and meta-analysis, this study reported that oral spironolactone showed a 56.60% overall improvement in female pattern hair loss, with better results in combination therapy, but emphasized the need for more research due to varied treatment responses and adverse event rates.

This randomized controlled trial found that methotrexate, particularly when combined with low-dose prednisone, was effective in promoting hair regrowth in patients with alopecia areata totalis, with the combination treatment showing higher efficacy and faster results.

This review examines metformin use in PCOS treatment, noting that while non-randomized studies show improvements, randomized controlled trials suggest benefits are limited and highlight lifestyle changes as potentially more effective.